Glucobay
In brief
- In our pharmacy, you can buy Glucobay without a prescription, with delivery in 9–21 days throughout the United Kingdom. Discreet and anonymous packaging.
- Glucobay (acarbose) is used to treat type 2 diabetes mellitus to reduce post‑prandial blood glucose; it is an alpha‑glucosidase inhibitor that delays intestinal carbohydrate digestion and absorption.
- The usual dose for adults is to start with 50 mg three times daily with the first bite of each main meal, increasing to 100 mg three times daily after 6–8 weeks as tolerated; the maximum recommended dose is 200 mg three times daily.
- Form of administration: oral tablet (available in 50 mg and 100 mg strengths).
- Onset time: begins to work during the meal, typically within 30–60 minutes, reducing post‑prandial glucose from the first dose.
- Duration of action: effect lasts for the duration of the meal and the following hours, typically up to around 4–6 hours after dosing.
- Alcohol warning: avoid excessive alcohol as it may worsen glycaemic control and increase the risk of hypoglycaemia and hepatic effects; exercise caution and seek medical advice if concerned. If hypoglycaemia occurs while taking acarbose, treat with pure glucose (dextrose), not ordinary sugar/sucrose.
- The most common side effects are flatulence and abdominal pain (very common); diarrhoea, bloating and transient increases in liver transaminases may also occur.
- Would you like to try Glucobay without a prescription?
Basic Glucobay information
- INN (international nonproprietary name): Acarbose
- Brand names available in the United Kingdom: Glucobay (tablets 50 mg, 100 mg)
- ATC code: A10BF01
- Forms and dosages: Tablet — 50 mg, 100 mg (oral)
- Manufacturers in the United Kingdom: Bayer
- Registration status in the United Kingdom: Prescription-only medicine (POM)
- OTC / Rx classification: Prescription-only (Rx)
Critical warnings and restrictions
High-risk groups (elderly, pregnancy, chronic illness)
Patients should be informed that acarbose (Glucobay) is a prescription-only medicine that must be supplied under professional supervision.
Do not prescribe Glucobay for patients with chronic intestinal disease such as inflammatory bowel disease, colonic ulceration or partial intestinal obstruction.
Do not prescribe Glucobay to patients with hepatic impairment or severe renal impairment (creatinine clearance below 25 mL/min).
Do not give Glucobay to anyone with known hypersensitivity to acarbose or any excipients in the formulation.
- Absolute contraindications: chronic intestinal disease; colonic ulceration; partial intestinal obstruction; hepatic impairment; severe renal impairment (creatinine clearance <25 mL/min); hypersensitivity to acarbose or excipients.
Raised transaminases can occur, so liver function should be monitored, particularly during the first months of treatment.
Elderly patients do not have a routine dose reduction but must be monitored for gastrointestinal intolerance and possible changes in liver enzymes.
Pregnancy and breastfeeding data are limited and Glucobay should be avoided unless a diabetes specialist advises otherwise.
Arrange pre-conception review and antenatal diabetes team review before starting or continuing acarbose in pregnancy.
Checklist before prescribing:
- Baseline liver function tests (LFTs).
- Baseline renal function including serum creatinine.
- Review medical history for chronic intestinal disease or cirrhosis.
Interaction with activities (driving, workplace safety under UK law)
Acarbose rarely causes hypoglycaemia when used alone, but the risk rises when combined with insulin or sulfonylureas.
Because acarbose delays carbohydrate absorption, ordinary sugar (sucrose) does not reliably correct hypoglycaemia while the drug is active.
Always treat hypoglycaemia with pure glucose (dextrose) or glucose tablets rather than sugary foods that rely on sucrose.
Patients who drive or operate machinery must be counselled about delayed hypoglycaemia and the need to carry a reliable source of glucose.
- Safety kit for drivers/workers: glucose tablets (dextrose), an ID card stating acarbose use, recent glucose monitor readings to show control.
Advise patients to report significant or unexpected adverse events to the MHRA via the Yellow Card scheme.
Q&A — “Can I drive after taking it in the UK?”
Short answer: Yes, if your diabetes is stable and you are not experiencing hypoglycaemia.
If a hypoglycaemic episode occurs while taking acarbose — especially when used with insulin or a sulfonylurea — do not drive until fully recovered.
Record any episodes of hypoglycaemia and inform your prescriber and pharmacist so treatment and driving advice can be reviewed.
- Checklist for drivers: carry glucose tablets; log hypoglycaemia episodes with date/time and treatment given; inform GP/diabetes nurse and consider notifying DVLA if episodes are recurrent.
Usage basics
INN, brand names available in the UK
International Nonproprietary Name (INN) is acarbose.
In the UK, acarbose is available as Glucobay (Bayer).
- INN
- Acarbose
- Brand
- Glucobay
- Form
- Tablet (oral) — 50 mg, 100 mg
Legal classification (POM, P, GSL)
Acarbose is a prescription-only medicine (POM) in the UK and must be supplied in line with MHRA and NHS prescribing rules.
Electronic Prescription Service (EPS) is commonly used in primary care to send prescriptions to nominated pharmacies.
- Patient ID requirements: standard proof of identity and a valid prescription where required.
- EPS notes: ensure pharmacy has access to recent test results and monitoring notes where available.
- Private prescribing: may occur via private endocrinology or diabetes clinics, but the product remains a POM.
Always confirm pack contents and dosing at the point of supply because strengths and packaging may vary by manufacturer.
Dosing guide
Standard regimens (NHS guidelines)
Start adults on 50 mg three times daily with the first bite of each main meal.
Increase to 100 mg three times daily after 6–8 weeks as tolerated and if additional glycaemic control is required.
The maximum recommended dose is 200 mg three times daily.
Timing is crucial: each dose must be taken with the start of the meal to work on postprandial carbohydrate digestion.
Titration checklist:
- Begin at 50 mg with each main meal to reduce GI side-effects.
- Assess tolerability and side-effects such as flatulence and diarrhoea before increasing dose.
- Consider raising to 100 mg three times daily after 6–8 weeks if needed and tolerated (maximum 200 mg three times daily).
- Monitor patient symptoms and glycaemic response during each titration step.
Adjustments for comorbidities
Acarbose is not established in children under 18 years and should not be used in this group unless under specialist advice.
Elderly patients do not require routine dose reduction but need closer monitoring for gastrointestinal effects and for liver enzyme changes.
Do not use acarbose in patients with severe renal impairment (creatinine clearance below 25 mL/min).
Do not use acarbose in hepatic impairment; transaminase elevations can occur during treatment.
Monitoring schedule:
- Baseline LFTs and renal function before initiation.
- Review LFTs and renal function at 1–3 months after starting.
- Periodic checks thereafter according to clinical judgment and local guidelines.
Q&A — “What if I miss a dose?”
If you miss a dose, take it with the next meal.
Do not double up or take a missed dose between meals.
If several hours have passed since the missed dose, skip it and continue the normal dosing schedule with the next meal.
Interaction chart
Food and drinks (alcohol, tea/coffee, diet habits)
Acarbose inhibits intestinal alpha-glucosidases and delays breakdown of carbohydrates, so its main effect is reducing post-meal glucose peaks.
Dietary composition determines both effect and side-effects, with starchy and sucrose-containing meals being most relevant.
Alcohol can mask the symptoms of hypoglycaemia and affect overall glycaemic control, so advise moderation.
| Meal type | Expected effect with acarbose |
|---|---|
| High-starch meals (bread, pasta, potatoes) | Reduced postprandial glucose spike; increased gas from fermentation |
| High-sucrose foods (table sugar) | Effect on postprandial glucose limited by delayed breakdown; hypoglycaemia treatment with sucrose may fail |
| Low-carb meals | Smaller impact from acarbose; fewer GI side-effects |
- Dietary tips: encourage smaller, regular meals with controlled starch content and counsel on carbohydrate counting if used as part of a wider diabetes plan.
- Always treat hypoglycaemia with pure glucose (dextrose) rather than ordinary sugar while on acarbose.
Common drug conflicts
The principal pharmacodynamic interaction is an increased risk of hypoglycaemia when acarbose is combined with insulin or sulfonylureas.
No major systemic pharmacokinetic interactions are described because acarbose acts locally in the gut and has minimal systemic absorption.
Transient liver enzyme elevations have been reported, so caution is warranted when combining with known hepatotoxic drugs.
| Drug class | Interaction | Recommended action |
|---|---|---|
| Insulin / sulfonylureas | Increased risk of hypoglycaemia | Reinforce glucose availability and monitoring; consider dose adjustment of concomitant agents |
| Hepatotoxic drugs | Potential for increased transaminases | Monitor LFTs closely; avoid combinations if alternative exists |
| Other antidiabetics | Use in combination possible under supervision | Monitor overall glycaemic control and hypoglycaemia signs |
Encourage patients and clinicians to report suspected adverse drug reactions to the MHRA Yellow Card scheme.
Legal status and availability in the UK
In our online pharmacy, Glucobay is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.
Mechanism and pharmacology
Simplified explanation
Acarbose is an alpha-glucosidase inhibitor that slows carbohydrate digestion at the brush border of the small intestine.
The drug delays the conversion of complex carbohydrates into absorbable monosaccharides, thereby reducing postprandial glucose excursions.
- Alpha-glucosidase
- Enzyme that breaks down carbohydrates in the small intestine.
- Effect
- Delayed glucose absorption and reduced post-meal blood glucose peaks.
Clinical terms
Pharmacological classification: ATC A10BF01.
Route of administration is oral tablets in 50 mg and 100 mg strengths.
- Clinical implications: useful as an adjunct for predominant postprandial hyperglycaemia; low systemic hypoglycaemia risk when used alone; gastrointestinal adverse events are common.
Indications and off-label uses
MHRA-approved uses
Main indication is type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control.
Acarbose can be used as monotherapy or in combination with other antidiabetic agents such as metformin, insulin or sulfonylureas under professional supervision.
Off-label practices in NHS and private care
Off-label use is limited; acarbose is not established for type 1 diabetes or for children under 18 years.
Some clinicians may trial acarbose for difficult postprandial hyperglycaemia where other agents are unsuitable or poorly tolerated.
- Off-label justifications: intolerance to other oral agents, targeting post-meal spikes specifically, or combining with other therapies under specialist supervision.
- Documentation checklist: record clinical reason for off-label use, obtain patient consent, and schedule monitoring for tolerability and LFTs.
Alternatives matrix
NHS prescribing alternatives (comparison table)
| Drug / class | Mechanism | Primary benefit | Common adverse effects | Suitability for postprandial control |
|---|---|---|---|---|
| Acarbose (alpha-glucosidase inhibitor) | Delays carbohydrate digestion | Targets post-meal glucose spikes | Flatulence, abdominal pain, diarrhoea, transient LFT rise | Good |
| Metformin | Reduces hepatic glucose output | Weight neutral, first-line for T2DM | GI upset, lactic acidosis rare | Moderate |
| Sulfonylureas | Increase insulin secretion | Effective for lowering glucose | Hypoglycaemia, weight gain | Limited |
| DPP-4 inhibitors | Enhance incretin effect | Well tolerated, low hypoglycaemia risk | Generally mild, rare pancreatitis reports | Moderate |
| SGLT2 inhibitors | Increase urinary glucose excretion | Cardio-renal benefits in selected patients | Genital infections, volume depletion | Limited |
| GLP-1 receptor agonists | Increase insulin, reduce appetite | Weight loss, strong glycaemic effect | Nausea, injection site reactions | Moderate |
Pros and cons checklist
- Pros: targets postprandial spikes, minimal weight gain, low systemic hypoglycaemia risk when used alone.
- Cons: high rate of gastrointestinal side-effects, need for LFT and renal monitoring, not suitable in significant renal or hepatic impairment.
- Prescriber checklist: consider patient diet, tolerance for GI effects, comorbidities, and an agreed monitoring plan.
Common questions
Will it make me gain weight?
Generally no; acarbose is weight-neutral or may be associated with modest weight effects due to altered carbohydrate absorption.
Can I drink alcohol?
Moderate alcohol intake is allowed but alcohol can mask hypoglycaemia and should be discussed if the patient uses insulin or sulfonylureas.
Is it safe in pregnancy?
Data are limited and acarbose should be avoided unless advised by a specialist; discuss risks and benefits with the diabetic pregnancy team.
How long before effects are seen?
Blunting of postprandial glucose occurs immediately with correct dosing at meals, while measurable HbA1c changes take several weeks to months.
- Follow-up advice: arrange review with GP or diabetes nurse to assess tolerability and clinical response within 1–3 months.
Registration and regulation
MHRA approval process
Acarbose is licensed in the UK as Glucobay.
The MHRA regulates licensing and post-marketing surveillance in the UK and clinicians should follow the summary of product characteristics (SPC) for up-to-date contraindications and monitoring.
- Regulatory checklist: confirm licence status, consult the SPC, and report suspected adverse reactions via the MHRA Yellow Card scheme.
NHS prescribing framework
Prescribing should follow NHS formularies and local commissioning guidance with appropriate monitoring for GI tolerance and liver function.
- Documentation to include: baseline labs, recorded consent for monitoring, and clear advice on hypoglycaemia management (use glucose, not sucrose).
- Pharmacy role: counsel patients on dosing with meals, side-effects, and provide glucose tablets where needed.
Storage and handling
UK household storage (cold / damp climate)
Store acarbose tablets below 25°C and protect from humidity.
In damp UK homes, keep tablets in the original blister pack and store in a cool, dry cupboard away from bathrooms or other humid rooms.
- Storage checklist: keep out of reach of children, check expiry dates, and avoid transferring tablets to organisers that expose them to moisture.
Guidance from NHS and pharmacists
Pharmacists should advise correct storage and the safe disposal of unused medicine via NHS pharmacy returns.
- Travel tips: carry medicine in original packaging, bring a copy of the prescription, and maintain temperature control where possible.
Guidelines for proper use
UK pharmacist counselling style
Use a structured counselling checklist at supply to verify identity, indication and the prescription details.
Explain that acarbose targets postprandial control in type 2 diabetes and must be taken with the first bite of each main meal.
Describe common side-effects (flatulence, diarrhoea) and the plan to titrate to improve tolerability.
Demonstrate how to use glucose tablets and emphasise that sucrose does not treat hypoglycaemia effectively while taking acarbose.
- Follow-up contact points: GP, diabetes nurse, and the dispensing pharmacy for review within 1–3 months.
NHS patient safety advice
Reinforce that acarbose complements diet and exercise and is not a substitute for regular monitoring.
Advise patients to stop and seek medical advice for severe abdominal pain, persistent diarrhoea or any signs of liver dysfunction including jaundice.
- Immediate actions: maintain a symptom log for clinic reviews and report suspected adverse reactions via the MHRA Yellow Card system.
Delivery across the United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | England | 9–21 days |
| Birmingham | England | 9–21 days |
| Manchester | England | 9–21 days |
| Glasgow | Scotland | 9–21 days |
| Liverpool | England | 9–21 days |
| Leeds | England | 9–21 days |
| Sheffield | England | 9–21 days |
| Bristol | England | 9–21 days |
| Newcastle Upon Tyne | England | 9–21 days |
| Belfast | Northern Ireland | 9–21 days |
| Cardiff | Wales | 9–21 days |
| Edinburgh | Scotland | 9–21 days |
| Nottingham | England | 9–21 days |
| Southampton | England | 9–21 days |
| Leicester | England | 9–21 days |
Final notes for patients and clinicians
Glucobay (acarbose) is a useful option when postprandial glycaemia is the main concern and when patients accept the risk of gastrointestinal side-effects for the metabolic benefit.
Always confirm a patient’s renal and liver function before initiation and during early therapy to reduce the risk of adverse effects.
When combined with insulin or sulfonylureas, counsel about hypoglycaemia and ensure clear plans to treat episodes with glucose, not sucrose.
Pharmacists and prescribers should document monitoring plans, provide clear written advice, and encourage reporting of suspected adverse reactions via the MHRA Yellow Card scheme.
For prescription questions or to arrange follow-up testing, contact your GP, diabetes clinic or the dispensing pharmacist listed on your prescription.